Stopping GLP-1s Linked to Double Heart Event Risk in T2D

Led by Antonio Ceriello at IRCCS MultiMedica, Polo Scientifico e Tecnologico in Milan, Italy, researchers used data from 301 diabetes clinics across Italy spanning 2004 to 2024.

The study evaluated 80,302 patients who started a GLP-1 RA, defining discontinuation as no prescription at two or more consecutive visits. Following propensity-score matching, analysts examined two balanced cohorts of 28,713 patients each, where the mean age was about 64.6 years and women made up 39.97% of each group.

The primary endpoint—a composite of nonfatal myocardial infarction, nonfatal stroke, or death from any cause—occurred at a rate of 3.94 per 100 person-years in the discontinuation group compared with 1.96 among persistent users.

All-cause death, evaluated as a secondary endpoint, reached 2.23 per 100 person-years after discontinuation versus 0.48 for persistent users. The association was also more pronounced in patients with a body mass index of 30 or higher, showing a hazard ratio of 2.27 compared to 1.61 for those with a BMI below 30.

GLP-1 Drug Discontinuation Linked to Higher Risk of Heart Attack and Stroke: Study — Medical Dialogues

“[The] results of our study show that people with T2D without CVD [cardiovascular disease] who started and then interrupted a therapy with a GLP-1RA have a higher risk of a composite endpoint of myocardial infarction, stroke, or death from any cause than those persisting on the same medication at a 4-year follow-up,” the authors wrote.

Study authors noted that such a large association “is unlikely to be explained solely by withdrawal of GLP-1RA therapy” and cautioned that discontinuation “may represent a higher underlying risk rather than a direct cause of increased cardiovascular risk.” The researchers emphasized that the observational design could not rule out unmeasured confounding, reverse causation, or the possibility that underlying illness prompted patients to stop treatment.

The work lacked data on socioeconomic factors and why patients stopped, did not record the cause of death, inconsistently captured heart-failure hospitalizations, and did not evaluate tirzepatide or patients using GLP-1 drugs solely for obesity.

Stopping glp linked to twice the risk of heart attack stroke or death in type diabetes
Photo: pharmaceutical-journal.com

Commenting on the research, Faye Riley, research communications lead at charity Diabetes UK, said: ““This was an observational study, so we can’t tell whether stopping taking GLP-1s directly raised people’s risk of heart attack and stroke, or if those who discontinued treatment were already experiencing health problems.””

Antonio Ceriello, who leads the diabetes department at IRCCS MultiMedica in Milan, has authored more than 450 original papers and holds an h-index of 88.

He chaired the International Diabetes Federation committee that produced the 2008 guideline on postmeal glucose management and its 2011 update, and he now presides over the European Association for the Study of Diabetes study group on diabetes and cardiovascular diseases. From July 2016 he has served as editor-in-chief of Diabetes Research and Clinical Practice, the official journal of the International Diabetes Federation.

Riley added:

New study shows the risk to heart health when users stop taking GLP-1 medications — CTV News

“The findings reinforce the importance of supporting people to stay on treatments that work for them. Anyone with T2DM who is considering stopping treatment should speak to their healthcare team first.”

Photo of author

Entertainment Desk

Entertainment Desk at Archyde.

TOP-REAL Study Uses Digital Tools to Detect Toxicities Early in HER2+ Breast Cancer

Leon Smith Steps Down as GB Davis Cup Captain After 17 Years